Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks is well positioned because zanidatamab has crossed a major de-risking event with FDA approval in 1L HER2-positive GEA, supported by strong Phase 3 data showing median PFS of 12.4 months versus 8.1 months and OS of 26.4 months versus 19.2 months in the triplet arm. The company also stands to receive a $250M milestone payment, with future royalties that could step up to 20% once annual sales exceed $2B, while its pro-forma cash position of $572.5MM supports development breadth. Beyond zanidatamab, advancing programs such as ZW191, ZW251, and the pan-RAS ADC platform add multiple longer-dated value drivers and make the equity look increasingly underappreciated.

Zymeworks is viewed negatively because its value remains highly dependent on high-risk clinical execution, with the bear case assuming zanidatamab’s commercial launch is underwhelming and assigning only a 10% POS to royalties and milestones in BTC and GEA while eliminating platform value. The company also faces substantial competitive, regulatory, manufacturing, and financing risks, and its pipeline assets such as ZW191 and ZW251 have only 10% to 35% POA, leaving limited margin for error if efficacy, safety, or FDA review disappoints. Even if some programs advance, the stock could still underperform due to dilution risk, uncertain market uptake, and the possibility that prolonged or unsuccessful strategic alternatives fail to unlock value.